Report an error

Spotted something inaccurate in “Dual GLP-1/Glucagon Receptor Agonist Survodutide Achieves Landmark Weight Loss in Phase 3”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.